Q-omics provides the consensus-scored ZRANB3 profile across patient tissues and cancer cell-line models. ZRANB3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZRANB3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ZRANB3 RNA expression shows 21,324 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where ZRANB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZRANB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZRANB3 survival associations across molecular data types. ZRANB3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZRANB3 RNA expression–survival associations across cancer types. High ZRANB3 expression shows unfavorable associations in KIRP, ACC, LGG, UCEC and LUAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZRANB3 RNA expression.
This table summarizes ZRANB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZRANB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZRANB3 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LUAD, LIHC and LUSC. The HNSC box plot shows higher ZRANB3 RNA expression in tumor versus normal tissue (log2 FC = +0.549, t-test p < 0.001).
This table shows molecular features associated with ZRANB3 in patient tissues and cancer cell lines. In patient samples, ZRANB3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZRANB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
